Filing Details
- Accession Number:
- 0001209191-17-066649
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-12-20 16:35:36
- Reporting Period:
- 2017-12-19
- Accepted Time:
- 2017-12-20 16:35:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1649245 | G. Phillip Febbo | 301 Penobscot Dr. Redwood City CA 94063 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-12-19 | 5,000 | $27.00 | 23,134 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-12-19 | 5,000 | $37.00 | 18,134 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-12-19 | 334 | $36.82 | 17,800 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) Holding | Disposition | 2017-12-19 | 5,000 | $0.00 | 0 | $27.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 9,710 | 2026-02-16 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017.
- Represents actual sale price.
- The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.
Billionaire Hedge Funds
